Cingulate Reports Positive Top-Line Fed/Fast Study Results for CTx-1301 Lead Asset

(24/7 MARKET NEWS) – Cingulate Inc. (NASDAQ: CING) reported, after yesterday’s afterhours, positive top-line results from the CTx-1301-003 study assessing the effect of food on absorption of its lead candidate CTx-1301, which demonstrated that CTx-1301 can be taken with or without food.

Cingulate is at $1.84, up $0.75 (+68.47%), on trading volume of 6.2 million premarket shares.

Its 52-week trading range is $0.664 to $2.20. It blew through multiple resistance levels and is targeting the $2 resistance level from August. It opened this morning’s premarket trading at $2.20 and, if it can break through that level, on strong volume, this would likely run to the $3 level, but it may pullback some before the regular session kicks off.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist